跳至主要内容
临床试验/CTRI/2025/12/099338
CTRI/2025/12/099338尚未招募不适用

Clinical Evaluation of a Novel Multiplex PCR Panel (LipL21, LipL32, LipL41) for Leptospirosis Diagnosis in Kancheepuram District

Farida Fahhima A1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年1月17日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
试验地点
1

研究概览

简要总结

Leptospirosis is an important re emerging zoonotic disease causing acute febrile illness in tropical regions including Tamil Nadu. Early diagnosis is challenging due to non specific clinical presentation and limited sensitivity of serological tests in the initial phase of illness. Microscopic agglutination test though considered the reference standard requires paired sera and is not useful for early clinical decision making. Polymerase chain reaction based methods can detect leptospiremia in the early acute phase and enable timely treatment.

This study aims to clinically evaluate a novel multiplex PCR panel named LEPTOPLEX targeting LipL21 LipL32 and LipL41 genes for the diagnosis of leptospirosis among clinically suspected adult patients in Kancheepuram district. Adult patients aged 18 to 65 years presenting with acute febrile illness suspected to be leptospirosis will be enrolled. Blood samples will be collected at baseline for LEPTOPLEX testing and compared with conventional PCR and serological testing. Convalescent samples will be collected for serological confirmation.

The primary outcome of the study is to assess the sensitivity and specificity of the LEPTOPLEX multiplex PCR assay at baseline during the acute phase of illness. Secondary outcomes include comparison of detection rates with conventional diagnostic methods assessment of turnaround time agreement with serological reference standard and gene wise positivity pattern.

The study is expected to generate evidence on the utility of LEPTOPLEX as a rapid and reliable diagnostic tool for early detection of leptospirosis and to support its potential use in endemic settings for improved case management and disease control

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Patients of all ages and genders presenting with clinical suspicion of leptospirosis and who can provide informed consent written consent for adults greater or equal to 18 years, and parental or guardian consent for minors.

排除标准

  • Non-suspected cases and patients unable to provide informed consent.

研究者

发起方
Farida Fahhima A
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr.Farida Fahhima A

Saveetha Medical College and Hospital

研究点 (1)

Loading locations...

相似试验